The 6 minute walk test (6MWT) is well established in the clinical assessment of heart failure, pulmonary hypertension and COPD. Its value as a submaximal stress test in the risk stratification of chronic stable ischae...The 6 minute walk test (6MWT) is well established in the clinical assessment of heart failure, pulmonary hypertension and COPD. Its value as a submaximal stress test in the risk stratification of chronic stable ischaemic syndromes is as yet not validated. 95 patients undergoing coronary angiography for assessment of chronic stable angina performed the 6MWT according to a modified protocol. The gamma correlation test indicated a moderately significant relationship between ECG changes plus symptoms at the end of the 6MWT and multi vessel coronary arterial disease. The T wave changes showed no significant correlation. Hence the 6MWT is a useful tool in the risk stratification of stable ischaemic syndromes which can be safely performed in a general ward prior to hospital discharge. It would be a useful preliminary test before planning a programme of cardiac rehabilitation.展开更多
Introduction: Although many cardiopulmonary patients require home care services, the 6-minute walk test (6MWT) is unusable in most dwellings for objectively evaluating exercise capacity because it requires a 20 - 30 m...Introduction: Although many cardiopulmonary patients require home care services, the 6-minute walk test (6MWT) is unusable in most dwellings for objectively evaluating exercise capacity because it requires a 20 - 30 meter hallway. To meet this need, we developed a 2-minute step test (2MST): stepping up and down an 8 inch step for 2 minutes (1 step = bilateral step up + step down). Purpose: Evaluate the statistical validity, reproducibility, and sensitivity of the 2MST in assessing exercise capacity. Method: We compared the heart rate, oxygen saturation and perceived exertion obtained during performance of 2MST with those obtained during the 6MWT. Results: Comparing 2MST and 6MWT in 158 subjects for validity, r = 0.925 (P Conclusion: The 2MST is valid, reproducible, sensitive, safe, well-tolerated, and is a suitable substitute for the 6MWT.展开更多
目的探讨参附注射液对老年性心瓣膜病临床治疗作用。方法选择60例老年性心瓣膜病随机分为治疗组和对照组两组,各30例。治疗组采用5%葡萄糖注射液250 m L+参附注射液60 m L静脉滴注,每天1次,疗程10 d;对照组采用5%葡萄糖注射液250 m L+...目的探讨参附注射液对老年性心瓣膜病临床治疗作用。方法选择60例老年性心瓣膜病随机分为治疗组和对照组两组,各30例。治疗组采用5%葡萄糖注射液250 m L+参附注射液60 m L静脉滴注,每天1次,疗程10 d;对照组采用5%葡萄糖注射液250 m L+丹参注射液20 m L静脉滴注,每天1次,疗程10 d。其他治疗用药两组相同。结果连续治疗10 d后,治疗组6 min步行试验(120±5.1)m,心脏彩超LEVF(0.70±0.07),脑钠肽(130±5.3)pg/m L,对照组6 min步行试验(100±4.5)m,心脏彩超LEVF(0.62±0.05),脑钠肽(180±4.5)pg/m L,差异有显著统计学意义(P<0.05)。结论参附注射液治疗老年性心瓣膜病疗效明显优于丹参注射液,值得临床推广。展开更多
文摘目的:观察补肺止咳膏对慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)稳定期患者生存质量的影响。方法:120例COPD稳定期患者随机分为观察组和对照组。观察组(60例)予补肺止咳膏联合舒利迭,对照组(60例)以舒利迭治疗,疗程均为180 d。观察治疗前后主要症状评分、肺功能以及6分钟步行试验(6 minute walk test,6MWT)情况。结果:治疗前后比较,观察组主要症状(咳嗽、咯痰、气短、喘息)评分均有明显下降(P<0.05);治疗后两组间比较,观察组以上症状评分均低于对照组(P<0.05)。观察组肺功能第1秒用力呼气容积(forced expiratory volume in one second,FEV1)占用力肺活量(forced vital capacity,FVC)百分比(FEV1/FVC%)显著升高(P<0.05),观察组FEV1/FVC%高于对照组(P<0.05);观察组治疗后6MWT积分低于治疗前(P<0.05),低于对照组(P<0.05)。结论:补肺止咳膏联合舒利迭能更好改善COPD稳定期患者生存质量。
文摘The 6 minute walk test (6MWT) is well established in the clinical assessment of heart failure, pulmonary hypertension and COPD. Its value as a submaximal stress test in the risk stratification of chronic stable ischaemic syndromes is as yet not validated. 95 patients undergoing coronary angiography for assessment of chronic stable angina performed the 6MWT according to a modified protocol. The gamma correlation test indicated a moderately significant relationship between ECG changes plus symptoms at the end of the 6MWT and multi vessel coronary arterial disease. The T wave changes showed no significant correlation. Hence the 6MWT is a useful tool in the risk stratification of stable ischaemic syndromes which can be safely performed in a general ward prior to hospital discharge. It would be a useful preliminary test before planning a programme of cardiac rehabilitation.
文摘Introduction: Although many cardiopulmonary patients require home care services, the 6-minute walk test (6MWT) is unusable in most dwellings for objectively evaluating exercise capacity because it requires a 20 - 30 meter hallway. To meet this need, we developed a 2-minute step test (2MST): stepping up and down an 8 inch step for 2 minutes (1 step = bilateral step up + step down). Purpose: Evaluate the statistical validity, reproducibility, and sensitivity of the 2MST in assessing exercise capacity. Method: We compared the heart rate, oxygen saturation and perceived exertion obtained during performance of 2MST with those obtained during the 6MWT. Results: Comparing 2MST and 6MWT in 158 subjects for validity, r = 0.925 (P Conclusion: The 2MST is valid, reproducible, sensitive, safe, well-tolerated, and is a suitable substitute for the 6MWT.
文摘目的探讨参附注射液对老年性心瓣膜病临床治疗作用。方法选择60例老年性心瓣膜病随机分为治疗组和对照组两组,各30例。治疗组采用5%葡萄糖注射液250 m L+参附注射液60 m L静脉滴注,每天1次,疗程10 d;对照组采用5%葡萄糖注射液250 m L+丹参注射液20 m L静脉滴注,每天1次,疗程10 d。其他治疗用药两组相同。结果连续治疗10 d后,治疗组6 min步行试验(120±5.1)m,心脏彩超LEVF(0.70±0.07),脑钠肽(130±5.3)pg/m L,对照组6 min步行试验(100±4.5)m,心脏彩超LEVF(0.62±0.05),脑钠肽(180±4.5)pg/m L,差异有显著统计学意义(P<0.05)。结论参附注射液治疗老年性心瓣膜病疗效明显优于丹参注射液,值得临床推广。
